CA
NZ
UK
AU
IND
US
● Hyperfine has spent 2026 trying to convince the market that portable, point-of-care brain imaging can become a durable commercial business, and the stock's slide back below a dollar shows how much work remains.
Momentum in the U.S. breast-cancer treatment market has become the defining theme for IceCure Medical Ltd (NASDAQ:ICCM), the Israeli developer of minimally invasive cryoablation technology.
SeaStar Medical Holding Corporation (NASDAQ:ICU) gave investors a modest reason to cheer, with its shares climbing about 5% in a recent session. The Nasdaq-listed maker of a novel kidney-injury therapy, ticker ICU, has been building a commercial track record for QUELIMMUNE, its treatment for …
● The recent decline of roughly 3% is a small move with no single verified catalyst attached to the session, consistent with theVolatilitytypical of a sub-$1 stock.
● Gyre Therapeutics is a biopharmaceutical company built around anti-fibrotic therapeutics, and it reached its current form after a corporate combination that gave a U.S.-listed shell exposure to an established Chinese pharmaceutical operation.
Penny stocks rarely tell a clean story, and Halberd Corporation (OTC: HALB) is a case study in why. The shares change hands at a fraction of a cent on the OTC market, so a single-session move of a few percentage points translates into a …
Cue Health Inc (OTC:HLTHQ) was once a celebrated pandemic-era diagnostics story, a San Diego company whose portable molecular test brought lab-grade COVID-19 detection into the home. Today the shares trade for about a millionth of a dollar on the over-the-counter market under a ticker …
● Based in Waltham, Massachusetts, Werewolf Therapeutics is a clinical-stage biotechnology company built around its PREDATOR platform, which engineers conditionally activated INDUKINE molecules designed to release potent immune-stimulating cytokines preferentially within the tumor microenvironment.
An evocative name and a ticker at a hundred-thousandth of a cent make Hard To Treat Diseases Inc (OTC:HTDS) the kind of listing that turns up on speculative screens but almost nowhere else. The company holds itself out, at least by name, in the …
● Genelux has spent much of 2026 defined by a single question: can its oncolytic virus reach the finish line of a registrational trial before the cash clock runs out?.
Please wait processing your request...